News | April 06, 2009

Lantheus Acquires Rights to MRA Contrast Agent for Peripheral Vascular Imaging

April 7, 2009 - Lantheus Medical Imaging Inc. has acquired the U.S., Canadian and Australian rights to MS-325 (formerly marketed as VASOVIST, gadofosveset trisodium, by Bayer Schering Pharma) from EPIX Pharmaceuticals.

In December 2008, EPIX received FDA marketing approval for the magnetic resonance angiography (MRA) agent MS-325 to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. Currently, there are no other imaging agents approved for MRA in the U.S.

Under the terms of the agreement, Lantheus acquired the U.S. (including Puerto Rico), Canadian, and Australian rights to MS-325 from EPIX. EPIX will continue to own European and other ex-U.S. rights for the imaging agent. Lantheus is planning to launch MS-325 under a different name before the year-end.

MS-325 is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through MRA. MS-325 has been approved for marketing in the U.S. and in 37 countries outside the U.S.

For more information: www.lantheus.com.

Related Content

Materialise Receives FDA Clearance for Cardiovascular Planning Software Suite
Technology | Advanced Visualization | June 13, 2019
Three-dimensional (3-D) printing software and solutions company Materialise has received U.S. Food and Drug...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
SCCT Announces 2019 Gold Medal Award Recipients
News | Computed Tomography (CT) | June 05, 2019
The Society of Cardiovascular Computed Tomography (SCCT) will present the 2019 Gold Medal Award to Jonathon Leipsic, M....
At ACC 2019, Siemens unveiled a version of its go.Top CT optimized for cardiovascular imaging. The newly packaged scanner can generate data needed to do  CT-based FFR (fractional flow reserve).

At ACC 2019, Siemens unveiled a version of its go.Top CT optimized for cardiovascular imaging. The newly packaged scanner can generate data needed to do
CT-based FFR (fractional flow reserve).

Feature | Cardiac Imaging | May 31, 2019 | By Greg Freiherr
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the ann
Baylor Scott White Heart Hospital Siemens Flash CT system used for dedicated cardiac CT scans, CCTA, CTA.
360 Photos | CT Angiography (CTA) | May 20, 2019
This is a 360 degree photo of a Siemens Somatom Force 64-slice, dual-source computed tomography (CT) system installed
360 Photos | Cardiac Imaging | May 20, 2019
A 360 degree photo view of a Siemens Healthineers digital radiography (DR) room install and mobile Carestream DRX mob
360 Photos | Angiography | May 17, 2019
This is a view inside one of the 11 cath labs at ...
360 Photos | Magnetic Resonance Imaging (MRI) | May 17, 2019
This is a dedicated cardiac Siemens 1.5T MRI system installed at the Baylor Scott White Heart Hospital in Dallas.
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...